PEN Quote, Financials, Valuation and Earnings

ICU Medical has a net margin of 12.1% compared to Penumbra's net margin of -2.56%. Penumbra's return on equity of 3.62% beat ICU Medical's return on equity of -4.64%.

Penumbra has a consensus price target of $318.63, signalling upside risk potential of 25.79%. On the other hand ICU Medical has an analysts' consensus of $186.20 which suggests that it could grow by 38.49%. Given that ICU Medical has higher upside potential than Penumbra, analysts believe ICU Medical is more attractive than Penumbra.

Penumbra has a beta of 0.494, which suggesting that the stock is 50.568% less volatile than S&P 500. In comparison ICU Medical has a beta of 0.881, suggesting its less volatile than the S&P 500 by 11.918%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. ICU Medical pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than ICU Medical quarterly revenues of $604.7M. Penumbra's net income of $39.2M is higher than ICU Medical's net income of -$15.5M. Notably, Penumbra's price-to-earnings ratio is 238.97x while ICU Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.07x versus 1.36x for ICU Medical. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 12.1% compared to Penumbra's net margin of 30.99%. Penumbra's return on equity of 3.62% beat Intuitive Surgical's return on equity of 15.82%.

Penumbra has a consensus price target of $318.63, signalling upside risk potential of 25.79%. On the other hand Intuitive Surgical has an analysts' consensus of $575.49 which suggests that it could grow by 10.16%. Given that Penumbra has higher upside potential than Intuitive Surgical, analysts believe Penumbra is more attractive than Intuitive Surgical.

Penumbra has a beta of 0.494, which suggesting that the stock is 50.568% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.875%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Penumbra's net income of $39.2M is lower than Intuitive Surgical's net income of $698.4M. Notably, Penumbra's price-to-earnings ratio is 238.97x while Intuitive Surgical's PE ratio is 76.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.07x versus 21.76x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of 12.1% compared to Penumbra's net margin of 8.48%. Penumbra's return on equity of 3.62% beat Merit Medical Systems's return on equity of 9.19%.

Penumbra has a consensus price target of $318.63, signalling upside risk potential of 25.79%. On the other hand Merit Medical Systems has an analysts' consensus of $108.55 which suggests that it could grow by 14.99%. Given that Penumbra has higher upside potential than Merit Medical Systems, analysts believe Penumbra is more attractive than Merit Medical Systems.

Penumbra has a beta of 0.494, which suggesting that the stock is 50.568% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.662, suggesting its less volatile than the S&P 500 by 33.793%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than Merit Medical Systems quarterly revenues of $355.4M. Penumbra's net income of $39.2M is higher than Merit Medical Systems's net income of $30.1M. Notably, Penumbra's price-to-earnings ratio is 238.97x while Merit Medical Systems's PE ratio is 46.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.07x versus 4.08x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona has a net margin of 12.1% compared to Penumbra's net margin of 2.28%. Penumbra's return on equity of 3.62% beat Dentsply Sirona's return on equity of -35.57%.

Penumbra has a consensus price target of $318.63, signalling upside risk potential of 25.79%. On the other hand Dentsply Sirona has an analysts' consensus of $18.14 which suggests that it could grow by 12.62%. Given that Penumbra has higher upside potential than Dentsply Sirona, analysts believe Penumbra is more attractive than Dentsply Sirona.

Penumbra has a beta of 0.494, which suggesting that the stock is 50.568% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.215%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 3.97% to investors and pays a quarterly dividend of $0.16 per share. Penumbra pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.

Penumbra quarterly revenues are $324.1M, which are smaller than Dentsply Sirona quarterly revenues of $879M. Penumbra's net income of $39.2M is higher than Dentsply Sirona's net income of $20M. Notably, Penumbra's price-to-earnings ratio is 238.97x while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.07x versus 0.87x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.